Cargando…

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency

Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficie...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Antonin, Royer, Bernard, Boidot, Romain, Berthier, Joseph, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454/
https://www.ncbi.nlm.nih.gov/pubmed/37409256
http://dx.doi.org/10.3389/fonc.2023.1187052
_version_ 1785068254884003840
author Schmitt, Antonin
Royer, Bernard
Boidot, Romain
Berthier, Joseph
Ghiringhelli, François
author_facet Schmitt, Antonin
Royer, Bernard
Boidot, Romain
Berthier, Joseph
Ghiringhelli, François
author_sort Schmitt, Antonin
collection PubMed
description Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity.
format Online
Article
Text
id pubmed-10319454
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103194542023-07-05 Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency Schmitt, Antonin Royer, Bernard Boidot, Romain Berthier, Joseph Ghiringhelli, François Front Oncol Oncology Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity. Frontiers Media S.A. 2023-06-20 /pmc/articles/PMC10319454/ /pubmed/37409256 http://dx.doi.org/10.3389/fonc.2023.1187052 Text en Copyright © 2023 Schmitt, Royer, Boidot, Berthier and Ghiringhelli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Schmitt, Antonin
Royer, Bernard
Boidot, Romain
Berthier, Joseph
Ghiringhelli, François
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title_full Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title_fullStr Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title_full_unstemmed Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title_short Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
title_sort case report: 5-fluorouracil treatment in patient with an important partial dpd deficiency
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454/
https://www.ncbi.nlm.nih.gov/pubmed/37409256
http://dx.doi.org/10.3389/fonc.2023.1187052
work_keys_str_mv AT schmittantonin casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency
AT royerbernard casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency
AT boidotromain casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency
AT berthierjoseph casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency
AT ghiringhellifrancois casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency